Compare JCSE & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JCSE | TCRT |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 6.7M |
| IPO Year | 2022 | 2025 |
| Metric | JCSE | TCRT |
|---|---|---|
| Price | $1.22 | $2.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 20.5K | 18.0K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | ★ 8.18% | N/A |
| EPS Growth | N/A | ★ 24.66 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $1.67 |
| 52 Week High | $2.50 | $5.48 |
| Indicator | JCSE | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 40.17 |
| Support Level | $1.03 | $1.92 |
| Resistance Level | $1.32 | $2.84 |
| Average True Range (ATR) | 0.15 | 0.15 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 20.52 | 25.51 |
JE Cleantech Holdings Ltd is engaged in the manufacturing and selling of cleaning systems and other equipment that can be categorized into four different categories, namely aqueous washing systems, plating and cleaning systems, train cleaning systems, and other equipment, such as filtration units. The company is also into designing, developing, and manufacturing other cleaning systems for various industrial end-use applications using its R&D and engineering capabilities. The company has two operating segments namely sale of cleaning systems and other equipment and provision of centralized dishware washing and general cleaning services. Geographically, the company derives a majority of its revenue from Singapore.
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.